The investors have agreed to purchase the shares of common stock at a price of $6.57 per share, resulting in " /files//_onlineonline proceeds to Achillion of approximately $41.8 million. The sale was expected to close on "blog/buyvalium//#"> about September 4, subject to closing conditions.
The securities described above are being offered directly to the purchasers by Achillion pursuant to a registration statement previously filed with and subsequently declared effective by the Securities & Exchange Commission.
Achillion is a pharmaceutical developer focused on new treatments for patients with infectious disease, including HCV and resistant bacterial infections.
|< Prev||Next >|